Zuletzt geändert von Thomas Brinkmeier am 2025/04/25 20:40
<
Von Version < 22.1 >
bearbeitet von Thomas Brinkmeier
am 2025/04/09 22:09
Auf Version < 2.1 >
bearbeitet von Thomas Brinkmeier
am 2019/02/02 21:13
>
Änderungskommentar: Es gibt keinen Kommentar für diese Version

Zusammenfassung

Details

Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf
Author
... ... @@ -1,1 +1,0 @@
1 -XWiki.Dermatologie_Kompendium
Größe
... ... @@ -1,1 +1,0 @@
1 -620.9 KB
Inhalt
Wikiderm.EntryClass[0]
Eintrag
... ... @@ -59,63 +59,15 @@
59 59  (% class="Bullet" %)-(%%) Pyoderma gangraenosum
60 60  
61 61  (% class="Eintrag-2" %)
62 -(% class="Feature" %)TF:(%%) (% class="Bullet" %)-(%%) Infekte
62 +(% class="Feature" %)TF:(%%) Infekte
63 63  
64 64  (% class="Ebene-2" %)
65 65  (% class="Feature" %)Bsp:(%%) Mycoplasma pneumoniae, HIV
66 66  
67 -(% class="Ebene-1" %)
68 -(% class="Bullet" %)-(%%) Dupilumab
69 -
70 -(% class="Ebene-2" %)
71 -(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2023 Nov 27. [[http:~~/~~/doi.org/10.1111/ajd.14190>>url:http://doi.org/10.1111/ajd.14190]]
72 -
73 73  (% class="Eintrag-2" %)
74 -(% class="Feature" %)DD:(%%) (% class="Bullet" %)-(%%) AGEP
68 +(% class="Feature" %)DD:(%%) (% class="Abbreviation" %)AGEP(%%), Dermatitis herpetiformis, eosinophile pustulöse Follikulitis Ofuji, Impetigo contagiosa, Pemphigus foliaceus, Psoriasis pustulosa
75 75  
76 -(% class="Ebene-1" %)
77 -(% class="Bullet" %)-(%%) Dermatitis herpetiformis
78 -
79 -(% class="Ebene-1" %)
80 -(% class="Bullet" %)-(%%) eosinophile pustulöse Follikulitis Ofuji
81 -
82 -(% class="Ebene-1" %)
83 -(% class="Bullet" %)-(%%) Impetigo contagiosa
84 -
85 -(% class="Ebene-1" %)
86 -(% class="Bullet" %)-(%%) Pemphigus foliaceus
87 -
88 -(% class="Ebene-1" %)
89 -(% class="Bullet" %)-(%%) anuläre Psoriasis pustulosa
90 -
91 -(% class="Ebene-2" %)
92 -(% class="Feature" %)Bsp:(%%) annular pustular psoriasis
93 -
94 -(% class="Ebene-2" %)
95 -(% class="Feature" %)Lit:(%%) Pediatr Dermatol. 2023 Jan 31. [[http:~~/~~/doi.org/10.1111/pde.15251>>url:http://doi.org/10.1111/pde.15251]]
96 -
97 -(% class="Ebene-1" %)
98 -(% class="Bullet" %)-(%%) Tinea incognito
99 -
100 -(% class="Ebene-2" %)
101 -(% class="Feature" %)Lit:(%%) [[Kalkan, G., Demirseren, D. D, Güney, C. A, & Aktaş, A. (2020). A case of tinea incognito mimicking subcorneal pustular dermatosis. Dermatology Online Journal, 26(2)>>url:https://escholarship.org/uc/item/46g9x55w]]
102 -
103 103  (% class="Eintrag-2" %)
104 -(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) {{pdfbox Datei="Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf" /}}
105 -
106 -(% class="Ebene-1" %)
107 -(% class="Bullet" %)-(%%) Open Access Maced J Med Sci. 2020 Jun 05; 8(T1):12-15. [[https:~~/~~/doi.org/10.3889/oamjms.2020.4870>>url:https://doi.org/10.3889/oamjms.2020.4870]]
108 -
109 -(% class="Ebene-1" %)
110 -(% class="Bullet" %)-(%%) International Journal of Women's Dermatology, Volume 6, Issue 3, 2020, Pages 131-136, ISSN 2352-6475, [[https:~~/~~/doi.org/10.1016/j.ijwd.2020.02.003>>url:https://doi.org/10.1016/j.ijwd.2020.02.003]]
111 -
112 -(% class="Ebene-1" %)
113 -(% class="Bullet" %)-(%%) SAGE Open Med Case Rep. 2019 Jan 30;7:2050313X19826432. [[http:~~/~~/doi.org/10.1177/2050313X19826432>>url:http://doi.org/10.1177/2050313X19826432]]
114 -
115 -(% class="Ebene-1" %)
116 -(% class="Bullet" %)-(%%) JAAD Case Rep. 2022 Jan 21;21:185-188. [[http:~~/~~/doi.org/10.1016/j.jdcr.2021.04.039>>url:http://doi.org/10.1016/j.jdcr.2021.04.039]]
117 -
118 -(% class="Eintrag-2" %)
119 119  (% class="Feature" %)Th:(%%) (% class="Bullet" %)-(%%) lokal
120 120  
121 121  (% class="Ebene-2" %)
... ... @@ -122,12 +122,6 @@
122 122  (% class="Bullet" %)-(%%) Farbstoffe (**[[Antiseptika]]**)
123 123  
124 124  (% class="Ebene-2" %)
125 -(% class="Bullet" %)-(%%) Mometasonfuroat
126 -
127 -(% class="Ebene-3" %)
128 -(% class="Feature" %)Lit:(%%) Dermatol Ther. 2021 Nov 27:e15235. [[http:~~/~~/doi.org/10.1111/dth.15235>>url:http://doi.org/10.1111/dth.15235]]
129 -
130 -(% class="Ebene-2" %)
131 131  (% class="Bullet" %)-(%%) Tacalcitol
132 132  
133 133  (% class="Ebene-3" %)
... ... @@ -134,7 +134,7 @@
134 134  (% class="Feature" %)Lit:(%%) J Dermatol 2000; 27: 669-72
135 135  
136 136  (% class="Ebene-3" %)
137 -(% class="Feature" %)PT:(%%) CR
83 +(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%)
138 138  
139 139  (% class="Ebene-3" %)
140 140  (% class="Feature" %)Altn:(%%) Maxacalcitol
... ... @@ -143,14 +143,8 @@
143 143  (% class="Feature" %)Lit:(%%) Clin Exp Dermatol. 2015 May 19. [[http:~~/~~/doi.org/10.1111/ced.12680>>url:http://doi.org/10.1111/ced.12680]]
144 144  
145 145  (% class="Ebene-5" %)
146 -(% class="Feature" %)Lit:(%%) CR
92 +(% class="Feature" %)Lit:(%%) (% class="Abbreviation" %)CR(%%)
147 147  
148 -(% class="Ebene-2" %)
149 -(% class="Bullet" %)-(%%) Dapson Gel
150 -
151 -(% class="Ebene-3" %)
152 -(% class="Feature" %)Lit:(%%) J Dermatol. 2019 Jun 24. [[http:~~/~~/doi.org/10.1111/1346-8138.14953>>url:http://doi.org/10.1111/1346-8138.14953]]
153 -
154 154  (% class="Ebene-1" %)
155 155  (% class="Bullet" %)-(%%) systemisch
156 156  
... ... @@ -158,7 +158,7 @@
158 158  (% class="Bullet" %)-(%%) Dapson
159 159  
160 160  (% class="Ebene-3" %)
161 -(% class="Feature" %)Bed:(%%) GS
101 +(% class="Feature" %)Bed:(%%) (% class="Abbreviation" %)GS(%%)
162 162  
163 163  (% class="Ebene-3" %)
164 164  (% class="Feature" %)Dos:(%%) 100-150 mg/Tag
... ... @@ -194,15 +194,6 @@
194 194  (% class="Feature" %)Lit:(%%) Dermatol Ther. 2019 Jan 14:e12818. [[http:~~/~~/doi.org/10.1111/dth.12818>>url:http://doi.org/10.1111/dth.12818]]
195 195  
196 196  (% class="Ebene-2" %)
197 -(% class="Bullet" %)-(%%) Apremilast
198 -
199 -(% class="Ebene-3" %)
200 -(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]]
201 -
202 -(% class="Ebene-3" %)
203 -(% class="Bullet" %)-(%%) Australas J Dermatol. 2023 Aug;64(3):e310-e312. [[http:~~/~~/doi.org/10.1111/ajd.14073>>url:http://doi.org/10.1111/ajd.14073]]
204 -
205 -(% class="Ebene-2" %)
206 206  (% class="Bullet" %)-(%%) Anti-TNF-alpha
207 207  
208 208  (% class="Ebene-3" %)
... ... @@ -209,8 +209,14 @@
209 209  (% class="Feature" %)Stoff:(%%) (% class="Bullet" %)-(%%) **[[Infliximab]]**
210 210  
211 211  (% class="Ebene-4" %)
212 -(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4, Dermatol Ther. 2022 May 4:e15552. [[http:~~/~~/doi.org/10.1111/dth.15552>>url:http://doi.org/10.1111/dth.15552]]
143 +(% class="Feature" %)Phar:(%%) Remicade^^®^^
213 213  
145 +(% class="Ebene-4" %)
146 +(% class="Feature" %)Dos:(%%) 5 mg/kg i.v.
147 +
148 +(% class="Ebene-4" %)
149 +(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4
150 +
214 214  (% class="Ebene-3" %)
215 215  (% class="Bullet" %)-(%%) Adalimumab
216 216  
... ... @@ -219,10 +219,3 @@
219 219  
220 220  (% class="Ebene-5" %)
221 221  (% class="Feature" %)PT:(%%) CR
222 -
223 -(% class="Ebene-2" %)
224 -(% class="Bullet" %)-(%%) Guselkumab
225 -
226 -(% class="Ebene-3" %)
227 -(% class="Feature" %)Lit:(%%) Int J Dermatol. 2021 Apr;60(4):e153-e154. [[http:~~/~~/doi.org/10.1111/ijd.15311>>url:http://doi.org/10.1111/ijd.15311]]
228 -

Artikelinhalt

©WIKIDERM GmbH • Kontakt • FAQ • Impressum • Nutzungsbedingungen • Datenschutzerklärung • Facebook